Bonaldi Carolina M, Azzalis Ligia A, Junqueira Virginia B C, de Oliveira Claudia G B, Vilas Boas Viviane A, Gáscon Thaís M, Gehrke Flávia S, Kuniyoshi Renata K, Alves Beatriz C A, Fonseca Fernando L A
Department of Urology, ABC Medical School, Santo André, SP - Brazil.
Tumori. 2015 Mar-Apr;101(2):185-8. doi: 10.5301/tj.5000237. Epub 2015 Mar 1.
Prostate cancer is the most common malignant tumor in men. Serum prostate-specific antigen (PSA), Gleason score and clinical range at the time of diagnosis are important factors to predict prognosis and outcome after therapy but additional accurate and reliable biomarkers are still wanted. So far, few biomarkers of prostate cancer have been successfully implemented and are being used in clinical practice. However, modifications of E-cadherin and MMP-13 expression are likely to be involved in prostate cancer invasion and thus are potential biomarkers for prognosis.
We analyzed the concentrations of E-cadherin and MMP-13 in plasma of patients with prostate cancer at diagnosis and 3 and 6 months after the beginning of treatment and related these measures to free and total PSA and other clinical features.
The concentration of E-cadherin was lower in patients with prostate cancer compared to the control group, but there was no difference in the concentration of MMP-13 between these two groups. During treatment, however, we found no significant differences between the concentrations of MMP-13 and E-cadherin, but we observed a significant positive correlation between total PSA and E-cadherin plasma concentration at the third month of treatment and between total testosterone and MMP-13 plasma concentration before the start of treatment.
The results suggest that these parameters could be used both in the diagnosis and prognosis of prostate cancer.
前列腺癌是男性最常见的恶性肿瘤。血清前列腺特异性抗原（PSA）、 Gleason评分以及诊断时的临床分期是预测治疗后预后和结局的重要因素，但仍需要其他准确可靠的生物标志物。到目前为止，很少有前列腺癌生物标志物成功应用于临床实践。然而，E-钙黏蛋白和基质金属蛋白酶-13（MMP-13）表达的改变可能参与前列腺癌的侵袭，因此是潜在的预后生物标志物。
我们分析了前列腺癌患者诊断时、治疗开始后3个月和6个月血浆中E-钙黏蛋白和MMP-13的浓度，并将这些指标与游离PSA、总PSA及其他临床特征相关联。
前列腺癌患者E-钙黏蛋白浓度低于对照组，但两组MMP-13浓度无差异。然而，在治疗期间，我们发现MMP-13和E-钙黏蛋白浓度之间无显著差异，但观察到治疗第三个月时总PSA与血浆E-钙黏蛋白浓度之间以及治疗开始前总睾酮与血浆MMP-13浓度之间存在显著正相关。
结果表明这些参数可用于前列腺癌的诊断和预后评估。
